NUAK1

Across TCGA pan-cancer cohorts, NUAK1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NUAK1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher NUAK1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NUAK1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, OV, and COAD are the cancer types where NUAK1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.122	0.646	<.001	18	view →
OV	OS	Median	IV	0.170	0.758	.044	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.876	0.481	.045	4	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →
BLCA	OS	Median	IV	0.230	0.607	.004	3	view →
SKCM	DFS	Median	III,IV	0.213	0.659	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NUAK1–PAAD (OS)

Open the PAAD breakdown →